Sagimet Biosciences Inc. (SGMT)

4.5700 +0.1300 (+2.93%) As of 11:05AM EDT. Market open.

Sagimet Biosciences Inc.

155 Bovet Road
Suite 303
San Mateo, CA 94402
United States
650-561-8600
https://www.sagimet.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 8

Key executives

Name	Title	Pay	Exercised	Year born
Dr. George W. Kemble Ph.D.	Executive Chairman of the Board	484k	N/A	1962
Mr. David A. Happel	CEO, President & Director	836.18k	N/A	1962
Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D.	Chief Medical Officer	649.33k	N/A	1963
Mr. Urs Greber Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. Lucas Pelkmans Ph.D.	Co-Founder	N/A	N/A	N/A
Ms. Elizabeth Rozek Esq., J.D.	General Counsel & Chief Compliance Officer	N/A	N/A	1972
Dr. Marie O'Farrell Ph.D.	Senior Vice President of Research & Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Corporate governance

Sagimet Biosciences Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.